<DOC>
<DOCNO>EP-0623596</DOCNO> 
<TEXT>
<INVENTION-TITLE>
N-acylpyrrolidines or N-acylpiperidines having a guanidinyl- or amidinyl-substituted side chain as thrombin inhibitors.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3140	A61K3140	A61K314427	A61K314427	A61K31445	A61K31445	A61K3155	A61K3155	A61K3800	A61K3800	A61P700	A61P702	A61P900	A61P900	A61P4300	A61P4300	C07D20700	C07D20708	C07D20709	C07D21100	C07D21160	C07D21162	C07D22300	C07D22304	C07D22700	C07D22704	C07D40100	C07D40112	C07K500	C07K5062	C07K5065	C07K5068	C07K5072	C07K5078	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07K	C07K	C07K	C07K	C07K	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K38	A61K38	A61P7	A61P7	A61P9	A61P9	A61P43	A61P43	C07D207	C07D207	C07D207	C07D211	C07D211	C07D211	C07D223	C07D223	C07D227	C07D227	C07D401	C07D401	C07K5	C07K5	C07K5	C07K5	C07K5	C07K5	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Guanidinyl- or amidinyl-substituted 
heterocyclic thrombin inhibitors are provided which 

have the structure 

wherein n is 0, 1 or 2;
 

   R¹ is -A-R², -CO-A-R² or -SO₂-A-R²;
 

wherein R² is guanidine, amidine or amino, and A is 
an alkyl, alkenyl or alkynyl chain of 2 to 6 carbons; 

or
 

   R¹ is -(CH₂)
p
-A'-R
2'
 or -(CH₂)
p
-CO-A'R
2'
 where 
p is 0, 1 or 2, R
2'
 is amidine and A' is an 
azacycloalkyl or azaheteroalkyl ring of 4 to 8 atoms, 

optionally substituted by alkyl, CO or halo;
 

   R¹ is -(CH₂)
p
-A''-R
2''
, -(CH₂)
p
-CO-A''-R
2''
, or 
-(CH₂)
p
-SO₂-A''-R
2''
,
 

wherein R
2''
is guanidine, amidine or aminomethyl, and 
A'' is aryl or cycloalkyl;

 
   and R³, R⁴, R⁵ and R⁶ are as defined herein. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SQUIBB BRISTOL MYERS CO
</APPLICANT-NAME>
<APPLICANT-NAME>
BRISTOL-MYERS SQUIBB COMPANY
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DAS JAGABANDHU
</INVENTOR-NAME>
<INVENTOR-NAME>
KIMBALL SPENCER D
</INVENTOR-NAME>
<INVENTOR-NAME>
LAU WAN FANG
</INVENTOR-NAME>
<INVENTOR-NAME>
DAS, JAGABANDHU
</INVENTOR-NAME>
<INVENTOR-NAME>
Kimball, Spencer D.
</INVENTOR-NAME>
<INVENTOR-NAME>
LAU, WAN FANG
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The present invention relates to guanidinylor 
amidinyl-substituted methylamino heterocyclic 
compounds, which are thrombin inhibitors and thus 
useful in inhibiting formation of thrombi. The guanidinyl- or amidinyl-substituted 
methylamino heterocyclic thrombin inhibitors of the 
invention have the structure I 
including all stereoisomers thereof
 
wherein n is 0, 1 or 2;
 
 
   R¹ is -A-R², -CO-A-R² or -SO²-A-R²; 
wherein R² is guanidine, amidine or amino, and A is 
an alkyl, alkenyl or alkynyl chain of 2 to 6 carbons; 
or
 
   R¹ is -(CH₂)p-A'-R2' or -(CH₂)p-CO-A'R2' where 
p is 0, 1 or 2, R2' is amidine and A' is an 
azacycloalkyl, azaheteroalkyl or azaheteroalkenyl 
ring of 4 to 8 atoms, optionally substituted by 
alkyl, CO or halo as given by the structure: 
where X is CH₂, O, S, NH or CH=CH;
 
   m = 0, 1, 2, 3 or 4 if X = CH₂ or CH=CH;
 
   m = 2, 3 or 4 if X = O, S, NH; and
 
   Y₁, Y₂ are independently H, alkyl, halo or 
keto; or
 
   R¹ is -(CH₂)p-A''-R2'', -(CH₂)p-CO-A''-R2'', or 
-(CH₂)p-SO₂-A''-R2'',
 
wherein R2'' is guanidine, amidine or aminomethyl, 
A'' is aryl or cycloalkyl, and p is as defined above;
 
   R³ and R⁴ are independently hydrogen, lower 
alkyl, cycloalkyl, aryl, hydroxy, alkoxy, keto, 
thioketal, thioalkyl, thioaryl, amino or alkylamino; 
or R³ and R⁴ together with the carbons to which they 
are attached form a cycloalkyl, aryl, or heteroaryl 
ring;
 
   R⁵ is hydrogen, hydroxyalkyl, aminoalkyl, 
amidoalkyl, alkyl, cycloalkyl, aryl, arylalkyl, 
alkenyl, alkynyl, arylalkoxyalkyl, or an amino acid 
side chain, either protected or unprotected; and
 
 
   R⁶ is hydrogen, 
-SO₂R⁷ or -CO₂R⁷ 
(wherein R⁷ is lower alkyl, aryl or cycloheteroalkyl);
 
   including pharmaceutically acceptable salts 
thereof. The term "lower alkyl" or "alkyl" as employed 
herein by itself or as part of another group includes 
both straight and branched chain radicals of up to 18 
carbons, preferably 1 to 8 carbons, such as methyl, 
ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, 
pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, 
octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, 
dodecyl, the various branched chain isomers thereof, 
and the like as well as such groups including 1, 2 or 
3 halo substituents, an aryl substituent, an alkylaryl 
substituent, a haloaryl substituent, a cycloalkyl 
substituent, an alkylcycloalkyl substituent, an 
alkenyl substituent, an alkynyl substituent, hydroxy 
or a carbon substituent. The term "cycloalkyl" by itself or as part of 
another group includes
</DESCRIPTION>
<CLAIMS>
A compound having the structure 
 

including all stereoisomers, wherein n is 0, 1 or 2; 
   R¹ is -A-R², -CO-A-R² or -SO₂-A-R2; 

wherein R² is guanidine, amidine or amino, and A is 
an alkyl, alkenyl or alkynyl chain of 2 to 6 carbons; 

or 
   R¹ is -(CH₂)p-A'-R2' or -(CH₂)p-CO-A'R2' where 

p is 0, 1 or 2, R2' is amidine and A' is an 
azacycloalkyl, azaheteroalkyl or azaheteroalkenyl 

ring of 4 to 8 atoms, optionally substituted by 
alkyl, CO or halo as given by the strucutre: 

 
where X is CH₂, O, S, NH or CH=CH; p is 0, 1 or 2; 

   m = 0, 1, 2, 3 or 4 if X = CH₂ or CH=CH; 
   m = 2,3 or 4 if X = O, S, NH; and 

   Y₁, Y₂ are independently H, alkyl, halo or 
keto; or

 
   R¹ is -(CH₂)p-A''-R2'', -(CH₂)p-CO-A''-R2'', or 

-(CH₂)p-SO₂-A''-R2'', 
wherein R2''is guanidine, amidine or aminomethyl, and 

A'' is aryl or cycloalkyl; 
   R³ and R⁴ are independently hydrogen, lower 

alkyl, cycloalkyl, aryl, hydroxy, alkoxy, keto, 
thioketal, thioalkyl, thioaryl, amino or alkylamino; 

or R³ and R⁴ together with the carbons to which they 
are attached form a cycloalkyl, aryl or heteroaryl 

ring; 
   R⁵ is hydrogen, hydroxyalkyl, aminoalkyl, 

alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, 
amidoalkyl, arylalkoxyalkyl or an amino acid side 

chain, either protected or unprotected; and 
   R⁶ is hydrogen, 

 
-SO₂R⁷ or -CO₂R⁷ 

(wherein R⁷ is lower alkyl, aryl or cycloheteroalkyl); 
   including pharmaceutically acceptable salts 

thereof. 
The compound as defined in Claim 1 wherein 
R¹ is -A-R₂. 
The compound as defined in Claim 1 wherein 
R¹ is 


The compound as defined in Claim 1 wherein 
R¹ is -SO₂-A-R². 
The compound as defined in Claim 1 wherein 
R¹ is -(CH₂)p-A'-R2'. 
The compound as defined in Claim 1 wherein 
R¹ is 


The compound as defined in Claim 1 wherein 
R¹ is -(CH₂)p-SO₂A'R². 
The compound as defined in Claim 1 wherein 
R¹ is -(CH₂)p-A''-R2''. 
The compound as defined in Claim 1 wherein 
R¹ is -(CH₂)p-CO-A''-R2''. 
The compound as defined in Claim 1 
wherein R¹ is -(CH₂)p-SO₂-A''-R2''. 
The compound as defined in Claim 1 
wherein n is O. 
The compound as defined in Claim 1 
wherein R⁶ is 2-naphthylsulfonyl, H, 

benzyloxycarbonyl, t-butoxycarbonyl or 
methylsulfonyl. 
The compound as defined in Claim 1 
wherein R² is guanidine or ami
no. 
The compound as defined in Claim 1 
wherein n is O, R⁶ is 2-naphthylsulfonyl, H, methylsulfonyl, 

benzyloxycarbonyl or t-butoxycarbonyl, R⁵ 
is arylalkyl, hydroxyalkyl or benzyloxyalkyl, R³ is 

H, R⁴ is H and R¹ is 

The compound as defined in Claim 1 having 
the structure 


The compound as defined in Claim 1 which 
is [S-(R*,R*)]
-4-[(aminoiminomethyl)amino]-N-[[1-[3-hydroxy-2-[(2-naphthalenylsulfonyl)amino]
-1-oxopropyl]-2-pyrrolidinyl]
methyl]butanamide, 

or 
pharmaceutically acceptable salts thereof including 

its trifluoroacetate (1:1) salt; 
   [R-(R*,S*)]
-[2-[2-[[[4-[(aminoiminomethyl)amino]butyl]
amino]methyl]
-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]
carbamic acid, phenylmethyl 
ester, or pharmaceutically acceptable salts thereof 

including its trifluoroacetate (1:2) salt; 
   (2S)-N-[4-[[[1-(D-phenylalanyl)-2-pyrrolidinyl]
methyl]amino]
butyl]guanidine, 

or 
pharmaceutically acceptable salts thereof including 

its trifluoroacetate (1:2) salt; 
   [R-(R*,S*)]
-4-[(aminoiminomethyl)amino]-N-[[1-(2-amino-1-oxo-3-phenylpropyl)-2-pyrrolidinyl]
methyl]butanesulfonamide, 

or pharmaceutically 
acceptable salts thereof including its trifluoroacetate 

(1:2) salt; 
   [R-(R*,S*)]
-[2-[2-[[[[3-[(aminoiminomethyl)amino]propyl]
sulfonyl]amino]
methyl]-1-pyrrolidinyl-2-oxo-1-(phenylmethyl)ethyl]
carbamic acid, 1,1-dimethylethyl 
ester or pharmaceutically acceptable 

 
salts thereof including its trifluoro-acetate (1:1) 

salt; 
   [R-(R*,S*)]
-3-[(aminoiminomethyl)amino]-N-[[1-(2-amino-1-oxo-3-phenylpropyl)-2-pyrrolidinyl]
methyl]propanesulfonamide, 

or pharmaceutically 
acceptable salts thereof including its trifluoroacetate 

(1:2) salt; 
   [R-(R*,S*)]
-2-amino-1-[2-[[[4-(aminomethyl)phenyl]amino]
methyl]-1-pyrrolidinyl]
-3-phenyl-1-propanone, or pharmaceutically acceptable salts 
thereof including its trifluoroacetate (1:3) salt; 

   [R-(R*,S*)]-N-[2-[2-[[[4-(aminomethyl)phenyl]
amino]methyl]
-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]
-2-naphthalenesulfonamide, 
or pharmaceutically 

acceptable salts thereof including its trifluoroacetate 
(2:3) salt; 

   [R-(R*,S)]-2-amino-1-[2-[3-[(aminoiminomethyl)amino]
propyl]-1-pyrrolidinyl]
-3-phenyl-1-propanone, or pharmaceutically acceptable salts 
thereof including its trifluoroacetate (1:3) salt; 

   [S-(R*,S*)]-4-[(aminoiminomethyl)amino]
-N-[[1-[2-[(methylsulfonyl)amino]-1-oxo-3-phenylpropyl]
-2-pyrrolidinyl]methyl]
butanamide, or pharmaceutically 
acceptable salts thereof including its trifluoroacetate 

(1:1) salt; 
   [R-(R*,S*)]
-2-amino-1-[2-[[[4-(aminomethyl)phenyl]amino]
methyl]-1-pyrrolidinyl]
-3-phenyl-1-propanone, or pharmaceutically acceptable salts 
thereof including its trifluoroacetate (1:3) salt; 

   [R-(R*,S*)]-N-[2-[2-[[[4-(aminomethyl)phenyl]
amino]methyl]
-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]
-2-naphthalenesulfonamide, 
or 

pharmaceutically acceptable salts thereof including 
its trifluoroacetate (2:3) salt;

 
   [S-(R*,R*)]
-4-[(aminoiminomethyl)amino]-N-[[1-[3-hydroxy-2-[[(7-methoxy-2-naphthalenyl)sulfonyl]
amino]-1-oxopropyl]
-2-pyrrolidinyl]methyl]
butanamide, 
or pharmaceutically acceptable salts thereof 

including its trifluoroacetamide (1:1) salt; 
   [R-(R*,S*)]
-4-[(aminoiminomethyl)amino]-N-[[(1-(2-amino-1-oxo-3-phenylpropyl)-2-pyrrolidinyl]
methyl]butanamide, 

or pharmaceutically acceptable 
salts thereof including its trifluoroacetate (1:2) 

salt; 
   [R-(R*,S*)]
-N-[2-[2-[[[4-(aminoiminomethyl)phenyl]amino]
methyl]pyrrolidinyl]
-2-oxo-1-(phenylmethyl)ethyl]methanesulfonamide, 

or pharmaceutically 
acceptable salts thereof including its trifluoroacetate 

(1:1) salt; 
   [S-(R*,S*)]
-4-[[[1-(2-amino-1-oxo-3-phenylpropyl)-2-pyrrolidinyl]methyl]
amino]benzenecarboximidamide, 

or pharmaceutically acceptable salts 
thereof including its trifluoroacetate (1:2) salt; 

   [S-(R*,R*)]-4-[(aminoiminomethyl)amino]
-N-[[1-[3-hydroxy-2-[[(7-methoxy-2-naphthalenyl)sulfonyl]amino]
-1-oxopropyl]-2-pyrrolidinyl]
methyl]butanamide, 

or pharmaceutically acceptable salts thereof 
including its trifluoroacetamide (1:1) salt 

   [R-(R*,S*)]-N-[2-[2-[[[4-(aminoiminomethyl)phenyl]
amino]methyl]
pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]
methanesulfonamide, 
or pharmaceutically 

acceptable salts thereof including its trifluoroacetate 
(1:1) salt; 

   [1(S),2S]-1-(aminoiminomethyl)-N-[[1-[3-hydroxy-2-[(2-naphthalenylsulfonyl)amino]
-1-oxopropyl]-2-pyrrolidinyl]
methyl]-3-piperidinecarboxamide, 

or pharmaceutically acceptable salts 
thereof including its trifluoroacetate (1:1) salt;

 
   [S-(R*,R*)]
-1-(aminoiminomethyl)-N-[[1-[3-hydroxy-2-[(2-naphthalenylsulfonyl)amino]-1-oxopropyl]
-2-pyrrolidinyl]methyl]
-4-piperidinecarboxamide, 
or pharmaceutically acceptable salts 

thereof including its trifluoroacetate (1:1) salt; 
   N-[(S)-2-[(S)-2-[[[[1-(aminoiminomethyl)-3-piperidinyl]
acetyl]amino]
methyl]-1-pyrrolidinyl]
-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalenesulfonamide, 

or pharmaceutically acceptable salts thereof 
including its trifluoroacetate (1:1) salt; 

   [S-(R*,R*)]-N-[2-[2-[[[[1-(aminoiminomethyl)-4-piperidinyl]
acetyl]amino]
methyl]-1-pyrrolidinyl]
-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalenesulfonamide, 

or pharmaceutically acceptable salts thereof 
including its trifluoroacetate (1:1) salt; 

   [S-(R*,R*)]-N-[2-[2-[[[5-[(aminoiminomethyl)amino]
-1-oxopentyl]amino]
methyl]-1-pyrrolidinyl]
-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalenesulfonamide, 

or pharmaceutically acceptable salts thereof 
including its trifluoroacetate (1:1) salt; 

   [S-(R*,R*)]-N-[2-[2-[[[6-[(aminoiminomethyl)amino]
-1-oxohexyl]amino]
methyl]-1-pyrrolidinyl]
-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalenesulfonamide, 

or pharmaceutically acceptable salts thereof 
including its trifluoroacetate (1:1) salt; 

   [1S[2R*(3S*)]]-N-[2-[2-[[[[1-(aminoiminomethyl)-3-piperidinyl]
carbonyl]amino]
methyl]-1-pyrrolidinyl]
-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalenesulfonamide, 

or pharmaceutically 
acceptable salts thereof including its 

trifluoroacetate (1:1) salt; 
   [S-(R*,R*)]
-N-[2-[2-[[[7-[(aminoiminomethyl)amino]-1-oxoheptyl]
amino]methyl]
-1-pyrrolidinyl]-1-(hydroxymethyl)-2-oxoethyl]
-2-naphthalenesulfonamide, 
 

or pharmaceutically acceptable salts thereof 
including its trifluoroacetate (1:1) salt; 

   [1S[2R*(3R*)]]-N-[2-[2-[[[[1-aminoiminomethyl)-3-piperidinyl]
carbonyl]amino]
methyl]-1-pyrrolidinyl]
-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalenesulfonamide, 

or pharmaceutically 
acceptable salts thereof including its 

trifluoroacetate (1:1) salt. 
The compound as defined in Claim 1 which 
is 

   [S-(R*,R*)]-4-(aminomethyl)-N-[[1-[3-hydroxy-2-[(2-naphthalenylsulfonyl)amino]
-1-oxopropyl]-2-pyrrolidinyl]
methyl]benzamide, or salts thereof 

including the trifluoroacetate (1:1) salt; 
   [1S(2R*,3R*)]
-N-[2-[[[[1-(aminoiminomethyl)-3-piperidinyl]carbonyl]
amino]methyl]
-1-pyrrolidinyl]-1-(hydroxymethyl)-2-oxoethyl]
-α-toluenesulfonamide or 
salts thereof; 

   [1S(2R*,3R*)]-N-[2-[[[[1-(aminoiminomethyl)-3-piperidinyl]
carbonyl]amino]
methyl]-1-pyrrolidinyl]
-1-(carbomethoxymethyl)-2-oxoethyl-α-toluenesulfonamide 
or salts thereof; 

   [1S(2R*,3R*)]-N-[2-[[[[1-(aminoiminomethyl)-3-piperidinyl]
carbonyl]amino]
methyl]-1-pyrrolidinyl]
-1-(carboxamidomethyl)-2-oxoethyl]-α-toluenesulfonamide 

or salts thereof; 
   S-(R*,R*)]
-3-(aminomethyl)-N-[[1-[3-hydroxy-2-[(2-napthalenylsulfonyl)amino]-1-oxopropyl]
-2-pyrrolidinyl]methyl]
benzamide, or salts thereof 
including its trifluoroacetate (1:1) salt; 

   S-(R*,R*)]-4-(aminomethyl)-N-[[1-[3-hydroxy-2-[(2-napthalenylsulfonyl)amino]
-1-oxopropyl]-2-pyrrolidinyl]
methyl]benzeneacetamide, or salts 

thereof including its trifluoroacetate (1:1) salt;
 

   [S-(R*,R*)]-3-(aminomethyl)-N-[[1-[3-hydroxy-2-[(2-napthalenylsulfonyl)amino]
-1-oxopropyl]-2-pyrrolidinyl]
methyl]benzeneacetamide, or salts 

thereof including its trifluoroacetate (1:1) salt 
   [3S-
[3R*,3(R*,R*)]]-1-(minoiminomethyl)-N-[[1-[2-[(2-napthalenylsulfonyl)amino]
-1-oxopropyl]-2-pyrrolidinyl]
methyl]-3-piperidinecarboxamide, or 

salts thereof including its trifluoroacetate (2:3) 
salt; 

   [3S-[3R*,3(R*,R*)]]-1-(aminoiminomethyl)-N-[[1-[3-hydroxy-2-[[(4-methylphenyl)sulfonyl]
amino]-1-oxopropyl]
-2-pyrrolidinyl]methyl]
-3-piperidine-carboxamide, 
or salts thereof including its 

trifluoroacetate (1:1) salt; 
   [3S-[3R*,3(R*,R*)]
}-1-(aminoiminomethyl)-N-[[1-[3-hydroxy-2-[[carbobenzyloxy]amino]
-1-oxopropyl]-2-pyrrolidinyl]
methyl]-3-piperidine-carboxamide,or 

salts thereof including its 
trifluoroacetate (1:1) salt; 

   [1S[2(R*,S*)]]-N-[2-[[[[1-(aminoiminomethyl)-4-piperidinyl]
carbonyl]amino]
methyl]-1-piperidinyl]
-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalenesulfonamide, 

or salts thereof including its 
trifluoroacetate salt; 

   [S-(R*,R*)]-3-[(aminoiminomethyl)amino]
-N-[[1-[3-hydroxy-2-[[2-naphthalenesulfonyl]amino]
-1-oxopropyl]-2-pyrrolidinyl]
methyl]propionamide, or 

salts thereof including its trifluoroacetate salt; 
   [1S[2(R*,S*),(3R*)]]
-N-[2-[[[[1-(aminoiminomethyl)-3-piperidinyl]carbonyl]
amino]methyl]
-1-piperidinyl]-1-(hydroxymethyl)-2-oxoethyl]
-2-naphthalenesulfonamide, 
or salts thereof including 

its trifluoroacetate salt;
 

   [1S[2R*]]-N-[2-[[[[1-(aminoiminomethyl)-3-phenyl]
carbonyl]amino]
methyl]-1-pyrrolidinyl]
-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalenesulfonamide, 

or salts thereof including its trifluoroacete salt; 
   [1S[2R*]]
-N-[2-[[[[1-(aminoiminomethyl)-cis-5-methyl-3-piperidinyl]carbonyl]
amino]methyl]
-1-pyrrolidinyl]-1-(hydroxymethyl)-2-oxoethyl]
-2-naphthalenesulfonamide, 
or salts thereof including 

its trifluoroacetate salt; 
   [1S[2R*]]
-N-[2-[[[[1-(aminoiminomethyl)-trans-5-methyl-3-piperidinyl]carbonyl]
amino]methyl]
-1-pyrrolidinyl]-1-(hydroxymethyl)-2-oxoethyl]
-2-naphthalenesulfonamide, 
or salts thereof including 

its trifluoroacetate salt; 
   [1S(2R*,3R*,4R*)]
-N-[2-[[[[1-(aminoiminomethyl)-3-piperidinyl]carbonyl]
amino]methyl]
-1-pyrrolidinyl]-1-(1-hydroxyethyl)-2-oxoethyl]
-2-naphthalenesulfonamide, 
or salts thereof including 

its trifluoroacetate salt; 
   [1S(2R*,3S*,4R*)]
-N-[2-[[[1-(aminoiminomethyl)-3-piperidinyl]carbonyl]
amino]methyl]
-1-pyrrolidinyl]-1-(1-hydroxyethyl)-2-oxoethyl]
-2-naphthalenesulfonamide, 
or salts thereof including 

its trifluoroacetate salt; 
   [R-(S*,R*)]
-N-[2-[2-[[[[1-(aminoiminomethyl)-4-piperidinyl]carbonyl]
amino]methyl]
-1-pyrrolidinyl]-1-(phenylmethyl)-2-oxoethyl]
methanesulfonamide, or 
salts thereof including its trifluoroacetate salt; 

   [S-(R*,R*)]-N-[2-[[[[1-(aminoiminomethyl)-3-piperidinyl]
carbonyl]amino]
methyl-1-pyrrolidinyl]-2-oxoethyl]
-2-naphthalenesulfonamide, or salts thereof 
including its trifluoroacetate salt; 

   [R-(S*,R*)]-N-[2-[2-[[[[1-(aminoiminomethyl)-4-piperidinyl]
carbonyl]amino]
methyl]-1-pyrrolidinyl]
- 
 

1-(methyl)-2-oxoethyl]benzylsulfonamide, or salts 

thereof including its trifluoroacetate salt. 
The compound as defined in Claim 1 having 
the formula 

 
or salts thereof including its trifluoroacetate salt; 

 
or salts thereof; 


 
or salts thereof; 

 
or salts thereof; 

 
or salts thereof inlcluding its trifluoroacetate 

salt; 

 

or salts thereof inlcluding its trifluoroacetate 
salt. 
A pharmaceutical composition comprising 
a compound as defined in any of Claims 1 to 18 and a 

pharmaceutically acceptable carrier therefor. 
Use of a compound as defined in any of 
Claims 1 to 18 for the preparation of a 

pharmaceutical composition for inhibiting or 
preventing formation of blood clots. 
</CLAIMS>
</TEXT>
</DOC>
